Physician profile
Zahid Vahora
NPI 1679716955
$419,745.75
in general payments reported to CMS, 2019-2025
28 companies · $308K in 2025
The $308K reported for 2025 was more than what 99% of Transplant Hepatology providers received nationally (typical 2025 total: $508).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,884 · 2020: $833 · 2021: $849 · 2022: $1,028 · 2023: $7,865 · 2024: $99K · 2025: $308K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $342K · Travel and Lodging: $54K · Consulting Fee: $9,908 · Food and Beverage: $9,667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $341,773.13 |
| Travel and Lodging | $53,804.19 |
| Consulting Fee | $9,907.50 |
| Food and Beverage | $9,667.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $359,341.97 | 2024-2025 | Rezdiffra, Resmetirom |
| Novo Nordisk INC | $29,426.41 | 2025 | Wegovy |
| Abbvie INC. | $23,999.76 | 2019-2025 | Mavyret |
| Genentech USA, INC. | $1,893.55 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,351.53 | 2019-2024 | Xifaxan, Plenvu |
| Gilead Sciences, INC. | $1,324.41 | 2019-2025 | |
| Boston Scientific Corporation | $628.46 | 2022-2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Intercept Pharmaceuticals, INC. | $408.35 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $275.59 | 2019-2024 | Ultomiris, Soliris |
| Mallinckrodt Hospital Products INC. | $234.68 | 2022-2025 | Terlivaz |
| Dilon Technologies, INC. | $203.26 | 2025 | Hemoblast Bellows |
| Sanofi-Aventis U.S. LLC | $137.06 | 2021 | |
| Sirtex Medical INC | $107.64 | 2019 | |
| Cook Medical LLC | $87.36 | 2022 | |
| Veloxis Pharmaceuticals, INC. | $51.98 | 2023-2024 | Envarsus |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $39.79 | 2020-2022 | |
| Astellas Pharma US INC | $30.40 | 2025 | Cresemba |
| Ethicon US, LLC | $28.22 | 2025 | Evarrest, Prolene, Surgicel Nu-Knit |
| Baxter Healthcare | $28.20 | 2023 | Floseal |
| Ipsen Biopharmaceuticals, INC | $25.83 | 2025 | Iqirvo |
| Shionogi INC | $23.86 | 2024 | Fetroja |
| Stryker Corporation | $19.39 | 2023 | Spy-Phi System |
| Exact Sciences Corporation | $18.79 | 2023 | Cologuard Collection Kit |
| Tetraphase Pharmaceuticals, INC. | $17.66 | 2019 | |
| Melinta Therapeutics, LLC | $15.71 | 2024 | Rezzayo |
| Shire North American Group INC | $14.65 | 2019 | |
| Eisai INC. | $11.24 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zahid Vahora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.